![]() Music |
![]() Video |
![]() Movies |
![]() Chart |
![]() Show |
![]() |
BEACON CRC: first-line bevacizumab in colorectal cancer treatment (VJOncology) View |
![]() |
FIRE-4.5: FOLFOXIRI plus either bevacizumab or cetuximab in mCRC (VJOncology) View |
![]() |
Upfront Bevacizumab and Cetuximab Compared in Metastatic Colorectal Cancer (OncLive) View |
![]() |
Bevacizumab and colorectal cancer in geriatrics (ecancer) View |
![]() |
Debate: Targeted therapy for RAS/BRAF WT left sided colon cancers - Bevacizumab or EGFR antibodies (HMP Education) View |
![]() |
Case 1: BRAF-Mutated Metastatic Colorectal Cancer (Targeted Oncology) View |
![]() |
Initial Management of Metastatic CRC in 2019 (HMP Education) View |
![]() |
Colorectal Cancer Debate: First Line BRAF V600E - FOLFOXIRI/Bev (HMP Education) View |
![]() |
2021 ASCO Direct Philadelphia | Colorectal Cancer Summary | Dr. Arturo Loaiza Bonilla (Total Health | Oncology) View |
![]() |
Targeting BRAF in Metastatic CRC (OncLive) View |